TGF-β Signaling Pathways in the Development of Diabetic Retinopathy
- PMID: 38474297
- PMCID: PMC10932130
- DOI: 10.3390/ijms25053052
TGF-β Signaling Pathways in the Development of Diabetic Retinopathy
Abstract
Diabetic retinopathy (DR), a prevalent complication of diabetes mellitus affecting a significant portion of the global population, has long been viewed primarily as a microvascular disorder. However, emerging evidence suggests that it should be redefined as a neurovascular disease with multifaceted pathogenesis rooted in oxidative stress and advanced glycation end products. The transforming growth factor-β (TGF-β) signaling family has emerged as a major contributor to DR pathogenesis due to its pivotal role in retinal vascular homeostasis, endothelial cell barrier function, and pericyte differentiation. However, the precise roles of TGF-β signaling in DR remain incompletely understood, with conflicting reports on its impact in different stages of the disease. Additionally, the BMP subfamily within the TGF-β superfamily introduces further complexity, with BMPs exhibiting both pro- and anti-angiogenic properties. Furthermore, TGF-β signaling extends beyond the vascular realm, encompassing immune regulation, neuronal survival, and maintenance. The intricate interactions between TGF-β and reactive oxygen species (ROS), non-coding RNAs, and inflammatory mediators have been implicated in the pathogenesis of DR. This review delves into the complex web of signaling pathways orchestrated by the TGF-β superfamily and their involvement in DR. A comprehensive understanding of these pathways may hold the key to developing targeted therapies to halt or mitigate the progression of DR and its devastating consequences.
Keywords: TGF-β; bone morphogenic proteins; cell signaling; diabetes mellitus; diabetic retinopathy; reactive oxygen species; retina; transforming growth factor-β.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures

Similar articles
-
Emerging Roles of Transforming Growth Factor β Signaling in Diabetic Retinopathy.J Cell Physiol. 2017 Mar;232(3):486-489. doi: 10.1002/jcp.25506. Epub 2016 Sep 21. J Cell Physiol. 2017. PMID: 27472503 Review.
-
Bone Morphogenetic Proteins and Diabetic Retinopathy.Biomolecules. 2021 Apr 18;11(4):593. doi: 10.3390/biom11040593. Biomolecules. 2021. PMID: 33919531 Free PMC article. Review.
-
Neurovascular regulation in diabetic retinopathy and emerging therapies.Cell Mol Life Sci. 2021 Aug;78(16):5977-5985. doi: 10.1007/s00018-021-03893-9. Epub 2021 Jul 7. Cell Mol Life Sci. 2021. PMID: 34230991 Free PMC article. Review.
-
The role of SIRT1 in diabetic retinopathy.Biomed Pharmacother. 2018 Jan;97:190-194. doi: 10.1016/j.biopha.2017.10.075. Epub 2017 Nov 6. Biomed Pharmacother. 2018. PMID: 29091865 Review.
-
Knockdown of NEAT1 exerts suppressive effects on diabetic retinopathy progression via inactivating TGF-β1 and VEGF signaling pathways.J Cell Physiol. 2020 Dec;235(12):9361-9369. doi: 10.1002/jcp.29740. Epub 2020 Apr 30. J Cell Physiol. 2020. PMID: 32356340
Cited by
-
Quercetin prevents rats from type 1 diabetic liver damage by inhibiting TGF-ꞵ/apelin gene expression.Curr Res Pharmacol Drug Discov. 2024 Sep 17;7:100201. doi: 10.1016/j.crphar.2024.100201. eCollection 2024. Curr Res Pharmacol Drug Discov. 2024. PMID: 39351284 Free PMC article.
-
Activated Growth Factor From Platelets as Treatment for Diabetic Retinopathy Through Antioxidant-Oxidative Stress Pathway.Diabetes Metab Syndr Obes. 2025 Jan 31;18:305-313. doi: 10.2147/DMSO.S490055. eCollection 2025. Diabetes Metab Syndr Obes. 2025. PMID: 39906695 Free PMC article.
-
Evaluation of Gene Expression and the Regulatory Role of microRNAs Related to the Mitogen-Activated Protein Kinase Signaling Pathway in Human Retinal Pigment Epithelial Cells Treated With Lipopolysaccharide A and Tacrolimus.Mediators Inflamm. 2025 Jul 1;2025:8586711. doi: 10.1155/mi/8586711. eCollection 2025. Mediators Inflamm. 2025. PMID: 40630080 Free PMC article.
-
Potential mechanisms of epigenetic regulation in diabetic retinopathy from the perspectives of multi-omics.Diabetol Metab Syndr. 2025 May 14;17(1):155. doi: 10.1186/s13098-025-01723-7. Diabetol Metab Syndr. 2025. PMID: 40369608 Free PMC article.
-
Therapeutic potential of integrins in diabetic retinopathy.World J Diabetes. 2025 May 15;16(5):101509. doi: 10.4239/wjd.v16.i5.101509. World J Diabetes. 2025. PMID: 40487599 Free PMC article. Review.
References
-
- Teo Z.L., Tham Y.C., Yu M., Chee M.L., Rim T.H., Cheung N., Bikbov M.M., Wang Y.X., Tang Y., Lu Y., et al. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic review and meta-analysis. Ophthalmology. 2021;128:1580–1591. doi: 10.1016/j.ophtha.2021.04.027. - DOI - PubMed
-
- Khan R., Yee Ooi X., Parvus M., Valdez L., Tsin A. Advanced Glycation End Products: Formation, Role in Diabetic Complications, and Potential in Clinical Applications. In: Grigsby J., Derbel F., editors. The Eye and Foot in Diabetes. IntechOpen; Rijeka, Croatia: 2020. [(accessed on 28 June 2023)]. Available online: https://www.intechopen.com/books/the-eye-and-foot-in-diabetes/advanced-g....
-
- Akla N., Viallard C., Popovic N., Lora Gil C., Sapieha P., Larrivée B. BMP9 (Bone Morphogenetic Protein-9)/Alk1 (Activin-Like Kinase Receptor Type I) Signaling Prevents Hyperglycemia-Induced Vascular Permeability. Arterioscler. Thromb. Vasc. Biol. 2018;38:1821–1836. doi: 10.1161/ATVBAHA.118.310733. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical